84 unique prescribers: this number is specific to Q3 (quarterly stat), not cumulative since launch.
Prescriber mix: about 50% split between new and returning prescribers, consistent across quarters.
Patient profile: nearly 90% of patients have prior ICI (immune checkpoint inhibitor) exposure.
Adjusted EBITDA breakeven: management expects to reach this at a revenue level of $700 million to $750 million, with no change in messaging.
Two main levers explaining the revenue range: (1) pace of enrollment in Phase III trials affecting R&D expenses, (2) launch-year dynamics impacting gross margin.
Mgmt stance: Neutral — reaffirms existing breakeven guidance for 2027 on a sustainable basis, noting the current quarter was close (minus $3 million); both levers are under management’s control.
Q7 — Emily Bodnar
Topic: Lung launch expectations, ramp for next year, and learnings for pancreatic launch
Key points:
Internal expectations adjusted: management is ensuring motivated field teams focus on right growth targets; investments in platform infrastructure will support the full portfolio (4 products on market by year-end).
Long-term value in non-small cell lung cancer: tremendous unmet need in second line, and LUNAR-2 trial offers a huge opportunity in first-line treatment.
Key learnings from lung launch: need for education beyond physicians — practices, nurses, and PAs must all be educated (patients may direct questions to any staff member).
For pancreatic launch: advantage of already being in market (physicians are not naive to the message); direct learning from lung regarding breadth of education needed.
Mgmt stance: Bullish — views lung as a hard but worthwhile opportunity due to long-term portfolio value, with incremental cost of spinning described as “quite negligible”; confident in platform investments and path to profitability.